Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients

Bone Marrow Transplantation

Volumn 42, Issue 4, 2008, Pages 275-279

  Langner, S ^a   Staber, P B ^a   Schub, N ^b   Gramatzki, M ^b   Grothe, W ^c   Behre, G ^c   Rabitsch, W ^d   Urban, C ^a   Linkesch, W ^a   Neumeister, P ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; NARCOTIC ANALGESIC AGENT; PALIFERMIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST SWELLING; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COATED TONGUE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; GINGIVA PAIN; HEART INFARCTION; HUMAN; INCIDENCE; INFECTION; LIP DISEASE; LIP PAIN; LIP SWELLING; MALE; MASTALGIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; ORAL MUCOSAL DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; TASTE; TONGUE SWELLING; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; FEMALE; FIBROBLAST GROWTH FACTOR 7; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMATITIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 51049096355     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.157     Document Type: Article

References (13)

1. Woo SB, Sonis ST, Monopoli MM, Sonis, AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612-1617.
2. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19 2201-2205.
3. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein ED. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539.
4. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-831.
5. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
6. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825-831.
7. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960-3967.
8. Blazar DR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216-3222.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
10. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
11. Buchheidt D, Bohme A, Cornely OA, Fatkenheuer G, Fuhr HG, Heussel G et al. Diagnosis and treatment of documented infections in neutropenic patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S127-S132.
12. Kruger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haernatology and Oncology. Ann Oncol 2005; 16: 1381-1390.
13. Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983-988.